Evaluation – 20220608 CSCC 2022 Symposium 4 Session Title: The Clinical Toxicology Lab and the Forgotten Public Health Crisis Presenters: Dr. Navdeep Tangri, Chair, Canadian Society of Nephrology Taskforce on Race and Kidney Function Ryan Sneath, Executive Director, EMS and Patient Transport Operations Dr. Byron Berenger, MSc, MD, FRCPC, D(ABMM), Medical Microbiologist, Calgary Laboratory Services & Provincial Lab Alberta Wade Hawkins, Southern Alberta Institute of Technology Objectives: At the conclusion of this session, participants will be able to: Identify the clinical scenarios where administration of POCT by non-laboratory personnel provides for greater access of health service Describe the role of the laboratory professional in delivery of POCT by non-lab professionals Identify the drivers of POCT standardization in non-laboratory setting Define the opportunity for resource stewardship in POCT in non-lab setting 1. Please rate the Sessions overall by choosing the appropriate number: Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly AgreeSufficient time was allowed for audience participation/active learning. One Two Three Four Five The facilities were satisfactory. One Two Three Four Five The session was free from commercial bias. One Two Three Four Five Overall, I would rate this Symposium as excellent. One Two Three Four Five 2. Please assess the Speaker by choosing the appropriate number: Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree The opioid crisis, drug checking and clinical laboratory: is there a link? - Dr. Christophe Stove, Ghent University, Laboratory of Toxicology Objectives: At the end of the session, the participants will be able to: Point out the advantages and limitations of microsampling Choose for what application(s) microsampling may be useful Discuss the utility of microsampling for toxicology testing Clarity of Voice One Two Three Four Five Met Stated Objectives One Two Three Four Five Balanced & Unbiased One Two Three Four Five Relevant to Practice Overall One Two Three Four Five Time for Active Learning One Two Three Four Five Comments3. Please assess the Speaker by choosing the appropriate number: Rating Scale: 1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly AgreeHarm reduction/Safe consumption sites, Drug Checking and Clinical Laboratories - Dr. Christiana Stefan, Clinical Biochemist/Toxicologist, Laboratory Director, Centre for Addiction and Mental Health Objectives: At the end of the session, the participants will be able to: Describe drug checking as a public health response to reduce the harms associated with substance use and prevent overdoseUnderstand the role of the clinical laboratory in drug checking and related legislative requirements in Canada Discuss the service goals of the Toronto’s Drug Checking Project for drug identification Evaluate the importance of advanced analytical strategies in the identification of novel drugs Discuss outcomes of Toronto’s Drug Checking Project regarding drug findings, laboratory, clinical and public health impactsClarity of Voice One Two Three Four Five Met Stated Objectives One Two Three Four Five Balanced & Unbiased One Two Three Four Five Relevant to Practice Overall One Two Three Four Five Time for Active Learning One Two Three Four Five Comments4. Please assess the Speaker by choosing the appropriate number: Rating Scale: 1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree Beyond the Sample: The humanity of harm reduction and opioid agonist therapy in Alberta - Christina Zagnelli, Outreach Team Nurse Practitioner, Alberta Health Services Objectives: At the end of the session, the participants will be able to: Develop an understanding of harm reduction strategies, challenge stigma and assumptions around substance use and the approaches needed to turn the tide on the public health crisis of drug poisonings; Integrate knowledge of established and emerging approaches to opioid agonist therapy into the clinical laboratory setting; Recognize the role of clinical chemistry in a public health crisis; demonstrate awareness of the broader social implications of provincial strategies to address the drug poisoning crisis, availability of harm reduction services, and the integration of novel opioid agonist therapies Clarity of Voice One Two Three Four Five Met Stated Objectives One Two Three Four Five Balanced & Unbiased One Two Three Four Five Relevant to Practice Overall One Two Three Four Five Time for Active Learning One Two Three Four Five Comments5. Please assess the Speaker by choosing the appropriate number: Rating Scale: 1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree Beyond the Sample: The humanity of harm reduction and opioid agonist therapy in Alberta - Rachel Edwards, UVIC Objectives: At the end of the session, the participants will be able to: Develop an understanding of harm reduction strategies, challenge stigma and assumptions around substance use and the approaches needed to turn the tide on the public health crisis of drug poisonings; Integrate knowledge of established and emerging approaches to opioid agonist therapy into the clinical laboratory setting; Recognize the role of clinical chemistry in a public health crisis; demonstrate awareness of the broader social implications of provincial strategies to address the drug poisoning crisis, availability of harm reduction services, and the integration of novel opioid agonist therapies Clarity of Voice One Two Three Four Five Met Stated Objectives One Two Three Four Five Balanced & Unbiased One Two Three Four Five Relevant to Practice Overall One Two Three Four Five Time for Active Learning One Two Three Four Five Comments6. As a result of attending this session, I am planning to: (please check one)a) Discuss the session with my colleagues Yes No b) Pursue additional learning activities. Yes No c) Complete a Personal Learning Project. Yes No d) Not change my practice. Yes No 3) Change my practice. Yes No 7. Please explain the change you are planning to make or the learning you plan to complete:8. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply) Medical Expert Communicator Collaborator Manager Health Advocate Scholar Professional 9. General comments about individual speakers10. What topics need to be addressed at future conferences to keep you up to date in your profession?Name Session Title Date Year Location Conference/Event CreditsEmail Session Code
